San Francisco, CA - There is promising news regarding the treatment of pancreatic cancer.
A new study found that combining cancer drugs nab-paclitaxel (Abraxane) and gemcitabine increases one and two-year survival rates for patients with metastatic pancreatic cancer.
The typical treatment method currently calls for using just one drug at a time.
Experts say the study could help reshape how pancreatic cancer is treated going forward.
